An opinion on the commercial prospects of RHY, page-10

Sorry to hear about your shabby treatment in other threads. I am a big fan of the ignore function when posters make it personal.

Yes, AP really does look like a case of management incompetence.

As part of my due diligence, I was in contact with RHY's new CEO, Glenn, recently. We touched on the competitive landscape, costs, etc. You may wish to contact him for a chat. I'm sure he could answer all of your questions. My takeaway is that cost is definitely a critical factor in terms of the adoption of a new test within the industry (but equally so is the participation rate).

Have you read the Sprout8 note on RHY? http://sprout8.com/rhy-research-report/

It mentions potential government support to accelerate commercialisation (given the low participation rates of the FIT test). The government appears keen to have the at risk population segment undergo an annual test. So, the sell may not be as difficult as it seems.

Not sure re: Trevor. The Sprout8 note mentions that he voluntarily moved from CSIRO to continue the ColoSTAT project. His continued involvement & links with CSIRO are mentioned as being important. TBH, I was happy (and relieved) that Glenn was internally promoted to the new CEO position. He has the business acumen to transition the company towards commercialisation, whereas Trevor can focus on the science.